JMP Says Executive Removals Will Not Materially Impact Optimer (OPTR)
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 31
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 31
Join SI Premium – FREE
JMP Securities' Liisa Bayko came to the defense of Optimer Pharma (Nasdaq: OPTR) Monday amid a 7 percent decline in the stock following news of the removal of the company's Chairman Michael Chang, CFO John Prunty and VP Youe-Kong Shue.
Bayko reassured the managerial shake up will not be an issue for the development of dificid and will not have a material impact on Optimer's stock.
JMP maintains a Market Outperform rating and $22 price target on shares of Optimer Pharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Optimer Pharma.
Bayko reassured the managerial shake up will not be an issue for the development of dificid and will not have a material impact on Optimer's stock.
JMP maintains a Market Outperform rating and $22 price target on shares of Optimer Pharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Optimer Pharma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
- AmerX Starts WidePoint Corp (WYY) at Buy
- FedEx (FDX) PT Lowered to $397 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst Comments, Momentum MoversRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
